About Tripartite motif-containing protein 44
Tripartite motif-containing protein 44 (TRIM44) is a protein
from Homo sapiens identified by UniProt accession
Q96DX7, 344 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Tripartite motif-containing protein 44 |
|---|
| UniProt accession | Q96DX7 |
|---|
| Gene | TRIM44 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 344 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (81)
Diseases linked to this target (Open Targets).
- isolated aniridia · score 0.37
- aniridia · score 0.34
- autosomal dominant compelling helio-ophthalmic outburst syndrome · score 0.29
- neurodegenerative disease · score 0.26
- non-small cell lung carcinoma · score 0.10
- neoplasm · score 0.09
- Miyoshi myopathy · score 0.09
- osteosarcoma · score 0.08
- gonorrhea · score 0.08
- squamous cell carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96DX7-F1 | alphafold | PREDICTED | 73.62 | — |
Amino-acid sequence (344 residues)
MASGVGAAFE ELPHDGTCDE CEPDEAPGAE EVCRECGFCY CRRHAEAHRQ KFLSHHLAEY VHGSQAWTPP ADGEGAGKEE AEVKVEQERE IESEAGEESE SEEESESEEE SETEEESEDE SDEESEEDSE EEMEDEQESE AEEDNQEEGE SEAEGETEAE SEFDPEIEME AERVAKRKCP DHGLDLSTYC QEDRQLICVL CPVIGAHQGH QLSTLDEAFE ELRSKDSGGL KAAMIELVER LKFKSSDPKV TRDQMKMFIQ QEFKKVQKVI ADEEQKALHL VDIQEAMATA HVTEILADIQ SHMDRLMTQM AQAKEQLDTS NESAEPKAEG DEEGPSGASE EEDT
Explore Tripartite motif-containing protein 44 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets